Cancer News and Research

Latest Cancer News and Research

Improving headache treatment could reduce health care spending, new study suggests

Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes.

8 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.

8 Jan 2015

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

8 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

New Horses and Hope campaign launched to raise $1 million for cancer screening mobile unit

Kentucky First Lady Jane Beshear today, along with representatives from the Kentucky Cancer Program, the University of Louisville's James Graham Brown Cancer Center and KentuckyOne Health, launched a new Horses and Hope campaign to raise $1 million for a mobile unit to provide free or significantly reduced cost cancer screenings to underserved populations across Kentucky.

7 Jan 2015

Dartmouth investigators create fast-track research tool to study mouse melanoma cell lines

Melanoma in humans is on the rise, with one in 50 individuals likely to have the disease. By developing cell lines that grow readily in culture, Dartmouth investigators led by Constance Brinckerhoff, PhD have created a fast-track research tool that remains applicable to many scientists who use mouse melanoma as a model system.

7 Jan 2015

Study: Almost 40% of people with abnormal results ignore bowel cancer screening tests

Almost 40 per cent of people who have abnormal results from bowel cancer screening tests and are referred for further investigation ignore their next screening invitation two years later, according to a Cancer Research UK study published today (Tuesday) in the British Journal of Cancer.

7 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

UCLA researchers develop method that defines unique stages of reprogramming skin cells

In a groundbreaking study that provides scientists with a critical new understanding of stem cell development and its role in disease, UCLA researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research led by Dr. Kathrin Plath, professor of biological chemistry, have established a first-of-its-kind methodology that defines the unique stages by which specialized cells are reprogrammed into stem cells that resemble those found in the embryo.

7 Jan 2015

New imaging technique measurably improves prostate cancer screening

In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men. Writing in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging - and may have significant implications for how patients with prostate cancer are ultimately treated.

6 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

Adding radiation treatment to hormone therapy saves older men with prostate cancer

Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from Penn Medicine researchers.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Cancer News and Research

Latest Cancer News and Research

Improving headache treatment could reduce health care spending, new study suggests

New guidance recommends use of primary HPV test for cervical cancer screening

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

New Horses and Hope campaign launched to raise $1 million for cancer screening mobile unit

Dartmouth investigators create fast-track research tool to study mouse melanoma cell lines

Study: Almost 40% of people with abnormal results ignore bowel cancer screening tests

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

UCLA researchers develop method that defines unique stages of reprogramming skin cells

New imaging technique measurably improves prostate cancer screening

U-M researchers reveal key gene that may provide potential target for cancer treatment

EnGeneIC closes oversubscribed Series B financing

Adding radiation treatment to hormone therapy saves older men with prostate cancer

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in